Adjunctive Risperidone in Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study
J Clin Psychiatry 2005;66(10):1321-1325
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Although significant advances
have been made in recent years in the treatment of
generalized anxiety disorder (GAD), many patients remain symptomatic despite ongoing
treatment, underscoring the need for adjunctive new
treatments to help improve response.
Method: Forty patients with a primary
diagnosis of DSM-IV GAD, who continued to experience GAD symptoms despite current
anxiolytic treatment of at least 4 weeks' duration,
as evidenced by Hamilton Rating Scale for Anxiety (HAM-A) total score >= 18 and Clinical
Global Impressions-Severity of Illness scale score
of moderate or greater, completed a 1-week screening phase and were then randomly assigned to
5 weeks of double-blind adjunctive treatment with placebo or risperidone at flexible doses of 0.5
to 1.5 mg/day. Patients continued to take their
anxiolytics throughout the study. The study was
conducted from June 2001 through March 2003.
Results: Adjunctive risperidone was
associated with statistically significant improvements
in core anxiety symptoms, as demonstrated by greater reductions in HAM-A total
scores (p = .034) and HAM-A psychic anxiety factor scores (p = .047) compared with placebo.
Although change scores on other outcome variables, including response rates, were higher in the risperidone group, differences did not achieve
Conclusion: Study findings suggest that
risperidone at low doses may represent a useful
tool in the management of symptomatic GAD patients.